Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1850331 | 1.00 | ACE (0.47) | ACEP2RX7 | |
| SCHEMBL159149 | 1.00 | ACE (0.47) | ACEP2RX7 | |
| SCHEMBL647325 | 1.00 | ACE (0.47) | ACEP2RX7 | |
| Ammonia Solution, Strong SCHEMBL11295703 | 0.98 | ACE (0.46) | ACEP2RX7 | |
| SCHEMBL16339447 | 0.88 | P2RX7 (0.44) | ACEP2RX7 | |
| SCHEMBL30813130 | 0.88 | P2RX7 (0.44) | ACEP2RX7 | |
| SCHEMBL16339048 | 0.88 | P2RX7 (0.44) | ACEP2RX7 | |
| SCHEMBL18212792 | 0.86 | ACE (0.44) | ACEP2RX7 | |
| SCHEMBL13949148 | 0.83 | P2RX7 (0.45) | P2RX7 | |
| SCHEMBL18101128 | 0.83 | P2RX7 (0.45) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0594608-B1 | CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESIS | RES CORP TECHNOLOGIES INC (US) | 1997-10-15 | — | — | EP | claimed |
| EP-4631573-A2 | TEAD INHIBITORS | Orion Corporation (FI) | 2025-10-15 | — | — | EP | disclosed |
| EP-4323338-B1 | TEAD INHIBITORS | ORION CORP (FI) | 2025-10-08 | — | — | EP | disclosed |
| US-20240246908-A1 | TEAD INHIBITORS | ORION CORPORATION (FI) | 2024-07-25 | — | — | US | disclosed |
| EP-4323338-A1 | TEAD INHIBITORS | Orion Corporation (FI) | 2024-02-21 | — | — | EP | disclosed |
| CN-117500786-A | TEAD inhibitors | 奥赖恩公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2022219246-A1 | TEAD INHIBITORS | ORION CORPORATION (FI) | 2022-10-20 | — | — | WO | disclosed |
| CN-114763356-A | Pyrrolobenzodiazepine compounds, and preparation method and application thereof | 沈阳药科大学 | 2022-07-19 | — | — | CN | disclosed |
| US-20210371422-A1 | MORPHINAN DERIVATIVE | NIPPON CHEMIPHAR CO., LTD. (JP) | 2021-12-02 | — | — | US | disclosed |
| US-20210371422-A1 | MORPHINAN DERIVATIVE | NIPPON CHEMIPHAR CO., LTD. (JP) | 2021-12-02 | — | — | US | disclosed |
| WO-2021071806-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
| EP-3498711-A1 | MORPHINAN DERIVATIVE | Nippon Chemiphar Co., Ltd. (JP) | 2019-06-19 | — | — | EP | disclosed |
| WO-2016142894-A1 | 3-SUBSTITUTED 1,3,4-OXADIAZOLE AND THIADIAZOLE COMPOUNDS AS IMMUNOMODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-09-15 | — | — | WO | disclosed |
| WO-2014144610-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2011049520-A1 | ADAMANTYL IMINOCARBONYL-SUBSTITUTED PYRIMIDINES AS INHIBITORS OF 1 1 BETAHSD1 | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | WO | disclosed |
| US-20110092526-A1 | Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826 | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| US-20090131444-A1 | Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| EP-1891078-A1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006125974-A1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131444-A1 | Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity | AAAS, AMPD2, AMPD3 | ACE 216/4885P2RX7 363/4885 |
| US-20240246908-A1 | TEAD INHIBITORS | TEAD3, TEAD1, TEAD2 | ACE 1563/4885P2RX7 1126/4885 |
| US-20210371422-A1 | MORPHINAN DERIVATIVE | OPRM1, HTR2B, HTR3D | ACE 3379/4885P2RX7 2771/4885 |
| US-20110092526-A1 | Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826 | HSD11B1, HSD17B11, HSD3B1 | ACE 269/4885P2RX7 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.